MIDD in Early Oncology Clinical Development: Dose Optimization

Home  /  Resources  /  White Paper  /  MIDD In Early Oncology Clinical Development : Dose Optimization & Beyond

MIDD In Early Oncology Clinical Development : Dose Optimization & Beyond

MIDD In Early Oncology Clinical Development

Dose optimization is a necessary method to ensure patients receive the appropriate amount of medicine and an important consideration as part of a long development process. By leveraging Model-Informed Drug Development (MIDD), dose optimization creates a path to keeping oncology clinical trials on pace from an early stage.

Download the Whitepaper

Request a Proposal

Featured Content

Understanding ICH E11A Key Features of the Pediatric Extrapolation Guideline and Implications for Sponsors

Blog

ICH E11A: Key Features and Implications of the Pediatric Extrapolation Guideline

Read More

The Expansion of Cell & Gene Therapies into Autoimmune Disease 

Infographic

Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease 

Read More
Rare Disease Clinical Trials: Challenges, Strategies, and Solutions for Success

Blog

Rare Disease Clinical Trials: Challenges, Strategies, and Solutions for Success

Listen Now

View All Resources

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Get In Touch

Join the A-Team

Want to help small and mid-sized biotech companies change the therapeutic landscape?

View Open Jobs

Subscribe to our monthly newsletter